SAN FRANCISCO (EGMN) - None of the common KRAS mutant alleles seen in metastatic colorectal cancer reliably predict benefit from panitumumab, new data show, suggesting that this agent should continue to be used only in patients with KRAS wild-type tumors.Investigators led by Dr. Marc Peeters of Antwerp University Hospital in Edegem, Belgium, analyzed data from a trio of phase III randomized trials of panitumumab (Vectibix), an antibody to epidermal growth factor receptor (EGFR), in more than 1,400...